An Integrated Radiolabelled Study To Determine The Mass Balance, Metabolite Profile And Identification And Absolute Bioavailability Of Nolasibanin Healthy Female Subjects

Nolasiban is an orally active oxytocin receptor antagonist under development by ObsEva S.A to enhance the receptivity of the endometrium to embryo implantation. As part of the development programme an open labelled, two part radiolabelled study was performed in female subjects. The study assessed the absorption and disposition of nolasiban after oral and intravenous (IV) administrations and enabled determination of mass balance, routes and rates of excretion and metabolism and absolute bioavailability.